Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...

Respiratory Care Devices Market Report, published by Allied Market Research, suggests that the global respiratory care ...

After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030 ...

French pharmaceutical giant Sanofi has removed Paul Hudson as chief executive, thanking him Thursday for "valuable ...

Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of ...

Investors pull away from Upstream as a twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing asthma exacerbations.

Upstream Bio, Inc. downgraded despite strong Verekitug phase 2 asthma results; assess anti-TSLP competition, dosing edge & catalysts. Click for this UPB update.

Do either of these ASX 200 companies appeal to you? The post Bargain buys! – Scoop up these ASX 200 stocks after yesterday's ...

Shares of Upstream Bio crashed Wednesday after the biotech's asthma drug succeeded in Phase 2 study, but with a more frequent dosing regimen.

Farid Manshaii KGI ’28 received the $40,000 Westly Prize for Young California Innovators on Jan. 26 for his health technology startup Recalivape, a harm-reduction system designed to help people quit ...